To further study the anti-tumor capacity of low-dose decitabine-pretreated CD4+ T cells in vivo, we performed a tumor-bearing xenograft model of mouse colon cancer MC38 cells and transferred low-dose decitabine-pretreated CD4+ T cells. This evidence concerns the gene CD4 and malignant colon neoplasm.